FridayOct 22, 2021 1:15 pm

Study Finds Diabetes, Heart Disease Risk Drops Among Psychedelics Users

A new study has found that individuals who have consumed a psychedelic substance at least once in their lives have decreased chances of developing diabetes or heart disease. The study was reported in the “Scientific Reports” journal. University of Oxford’s Otto Simonsson, the author of the study, stated that prior research had discovered links between lower chances of having hypertension and being obese or overweight and lifetime use of classic psychedelics, noting that hypertension and obesity were cardio-metabolic disease risk factors. Simonsson explained that the purpose of the research was to find the association between cardio-metabolic ailments such as heart…

Continue Reading

ThursdayOct 21, 2021 12:30 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announced Inclusion in AdvisorShares Psychedelics ETF; KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Tryp announced its inclusion in the AdvisorShares Psychedelics ETF The company hopes that its participation will open it up to a more diverse shareholder base and broaden its life science exposure Tryp’s presentation at the KCSA Virtual Investor Conference will also be available for on-demand viewing over the next 90 days Launched back in September 2021, the AdvisorShares Psychedelics Exchange-Traded Fund (“ETF”) has been actively trading, focusing on enterprises that have devoted a significant proportion of their assets to psychedelic drug development. Operating under the ticker symbol “PSIL” on the New York Stock Exchange (“NYSE”) Arca exchange, this fund has…

Continue Reading

ThursdayOct 21, 2021 11:30 am

The Psychedelics Sector Could Revolutionize Work

The psychedelics industry is flourishing and growing at a rapid rate as more states move to decriminalize the substances while others push for legalization. In the last few years, the market has seen significant growth in the number of drug-development companies that seek to get psychedelic compounds to be approved by the FDA. Projections show that in the next five years, psilocybin, which is the main active ingredient in magic mushrooms, and MDMA, which is also known as ecstasy, will be legal for prescription. Various studies have found that these substances possess medicinal benefits that may help treat various mental…

Continue Reading

WednesdayOct 20, 2021 2:45 pm

Study Finds That Pain Distribution Could Influence Patient Outcomes

A new study has found that reporting pain distribution on a map can help classify patients into subgroups that are linked to differences in pain impact, pain quality, pain intensity and clinically relevant outcomes. The study’s findings were published in the “Plos One” journal. Normally, the distribution of chronic pain across an individual’s body is used together with other symptoms and signs to diagnose and treat patients. Recent research on fibromyalgia shows that pain syndromes that are typically viewed as separate entities may share relevant features, particularly regarding the influence of the distribution of pain on outcomes. For their study,…

Continue Reading

WednesdayOct 20, 2021 1:42 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicine Cybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalation The company is pursuing the effectiveness of using inhalation as a delivery method for psychedelic medications Earlier this month, a Time magazine article reported on the “new era” of psychedelic medicine (https://ibn.fm/bfC3u). On the leading edge of this collective breakthrough is Cybin (NEO: CYBN) (NYSE American: CYBN), a company focused on progressing psychedelic therapeutics, addressing the mental health crisis and transforming the…

Continue Reading

TuesdayOct 19, 2021 12:30 pm

Study Finds MDMA-Assisted Psychotherapy Improves Sleep in PTSD Patients

A new study has found that MDMA-assisted psychotherapy may improve sleep in PTSD patients. The study’s findings were reported in the “Journal of Traumatic Stress.” Study author L. Jerome of the MAPS Public Benefit Corporation stated that the researchers were interested in learning whether MDMA-assisted therapy could decrease sleep difficulties in individuals with post-traumatic stress disorder and who suffer from disrupted sleep as a result. Jerome explained that being hypervigilant and having intrusive thoughts made it hard for individuals to get sleep, noting that slumber could also be interrupted by nightmares associated with trauma. In the report, she observed that…

Continue Reading

MondayOct 18, 2021 2:00 pm

Another California City Approves Measure to Decriminalize Psychedelic Substances

Last week, the city council of Arcata, California, decriminalized psychedelic substances. The measure, which was approved in a unanimous vote, will make the distribution, growing and possession of entheogenic substances such as ayahuasca and psilocybin among the lowest law-enforcement priorities in the city. This is in addition to calling upon the district attorney of Humboldt County to consider the measure’s intent when deciding whether to prosecute individuals involved in the use of entheogenic fungi and plants. The initiative further states that driving under the influence as well as the manufacturing and commercial sale of psychedelic substances remains prohibited. In an…

Continue Reading

FridayOct 15, 2021 11:00 am

Why We Should Change How We View Psychedelic-Assisted Psychotherapy

Research on psychedelics began long before the substances were made illegal in the 1970s. When they were banned, the promising research on the substances ground to a halt — until recently. The current search for alternative and effective treatments for various mental health conditions has renewed interest in these substances, which have been used by different Indigenous communities for centuries. Now, more people are opening up to the idea of psychedelic substances being used in combination with psychotherapy to treat mental health disorders. Psychedelic substances, which are sometimes referred to as hallucinogens, cause hallucinations. Examples of these substances include ayahuasca,…

Continue Reading

FridayOct 15, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with University of Wisconsin Researchers for Clinical Pharmacology Studies Evaluating TRP-8803

Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation The partnership is the latest in a series of collaborations as the company prepares for Phase 2b trials Tryp intends to use data from its Phase 2a clinical studies, expected to launch this year, coupled with preclinical data and clinical pharmacology data for TRP-8803, to support the use of the novel drug formulation in Phase 2b trials Tryp Therapeutics (CSE: TRYP)…

Continue Reading

ThursdayOct 14, 2021 12:15 pm

Official Tells Legislators That VA Is Following Psychedelics Studies for Veterans

During a recent Congressional hearing, Rep. Colin Allred revealed that the Department of Veterans Affairs (“VA”) has closely been following studies on the therapeutic benefits of psychedelic substances such as MDMA for veterans. The meeting, which was held last month before the House Veterans’ Affairs Committee, focused on innovative approaches to deal with suicide prevention in veterans. Officials had asked for an update on the study evaluating the use of psychedelic substances for the treatment of PTSD in military veterans, noting that there were good results from prior research on how psychedelic substances could help alleviate the mental health struggles…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050